Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOLVE-01: Experimental vs Authorized SARS-CoV-2 Vaccines as Booster in Healthy Adults
NCT07605520Phase 1Recruiting
- Sponsor
- ANRS
- Start
- May 2026
- Primary completion
- May 2028
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of CD40.RBDv and CD40 Pan-CoV in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by ANRS. Primary endpoints: Proportion of participants without any grade 3 or 4 adverse event and Geometric mean titers of neutralizing antibodies at Week 48. Started May 2026; status: recruiting.
02
Drugs
CD40.RBDvCD40 Pan-CoV
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07605520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07605520.